Janssen Research & Development
3210 Merryfield Row
About Janssen Research & DevelopmentAt Janssen Research & Development, LLC, we are united and energized by one mission – to discover and develop innovative medicines that ease patients' suffering, and solve the most important unmet medical needs of our time.
As one of the Janssen Pharmaceutical Companies, our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas:
• cardiovascular and metabolism, • immunology, • infectious diseases and vaccines, • neuroscience, and • oncology.
We think of the world as our laboratory and we look for innovation wherever it exists. This drives our relentless search for the best science, and our pursuit of collaborations and partnerships.
We believe there are no limits to what science can do. And we never lose sight of those who rely most on our discoveries.
Janssen Labs is part of Johnson & Johnson’s external research and development engine and provides a capital-efficient, resource-rich environment where independent emerging companies can progress their research. The 30,000 square foot flagship facility opened in early 2012 in San Diego at Janssen’s West Coast Research Center and currently hosts 30 emerging life science companies. Janssen Labs offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Janssen Labs is an open innovation model, and the agreement for space does not grant Janssen any stake in the companies, nor will the companies have a guaranteed future affiliation with Janssen; but the models is designed to initiate a dialogue early and foster long term relationships with innovators in healthcare.
130 articles about Janssen Research & Development
Janssen Research & Development Release: FDA Advisory Committee Recommends Accelerated Approval of Investigational Multi-Drug Resistant Tuberculosis Treatment Bedaquiline
Janssen Research & Development Release: Phase 3 Data Show Intravenous Golimumab Inhibited Radiographic Progression in Patients With Active Rheumatoid Arthritis
Janssen Research & Development Release: Phase 3 Results Show Canagliflozin as Add-on Therapy to Metformin and Pioglitazone Significantly Lowers Blood Sugar Levels in Adult Patients With Type 2 Diabetes
Janssen Research & Development Release: New One-Year Phase 3 Study Results Show Anti-TNF SIMPONI® Maintained Clinical Response in Treatment of Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development Release: Crohn's Disease Patients Refractory to Tumor Necrosis Factor Inhibitors Showed Improvement in Disease With STELARA® Treatment
Janssen Research & Development Release: New ZYTIGA® (abiraterone acetate) Data on Pain and Function Presented at the ESMO 2012 Congress (European Society for Medical Oncology)
Janssen Research & Development and Johnson & Johnson to Present Latest Phase 3 Results for Canagliflozin in the Treatment of Patients With Type 2 Diabetes
Janssen Research & Development to Present Latest Phase 3 Results for Canagliflozin in the Treatment of Patients With Type 2 Diabetes